Objective: A major problem of arterial hypertension is that many hypertensive people are not treated or do not follow their treatment correctly. Nevertheless, a good adherence with antihypertensive medications significantly reduces cardiovascular complications. This study was aimed to analyze the treatment discontinuations and the adherence in a cohort of patients newly diagnosed with arterial hypertension. Design and method: The pharmaceutical treatment of 18706 new patients using for the first time an antihypertensive drug was followed during 5 years (2008–2012) with retrospectively collected administrative database of a Belgian health insurer. Adherence was measured using the medication possession ratio (MPR greater than 80%). We defined treatment discontinuation as interruption of drug treatment during at least 6 months. Results: 12% of the cohort permanently stopped the antihypertensive treatment after the first year. On average patients under 50 years interrupted the treatment during 6 months more than 4 times, while patients over age 50 have had 2 periods of interruption. The correlation between the absence of treatment discontinuation the first two years and the following three years was positive and significant (r = 0.84). Only 22.4% of the cohort were compliant with antihypertensive therapy during the 5 years of treatment. Over the period studied, the rate of compliance among patients receiving one antihypertensive ATC class increased significantly (from 63% to 75%), whereas it remained relatively stable for two combined (or sequential) ATC classes (55%-56%) and for multi ATC classes (42%-44%). Regardless of the treatment year, compliance was particularly poor among patients using beta blockers. The correlation between good compliance at the beginning of the treatment (the first two years) and good compliance the following years was positive and significant (r = 0.66). Conclusions: The study emphasizes the necessity of early detection of illness and continued treatment, allowing to avoid or delay complications. We also highlight the importance to take effective action early in the treatment to improve the compliance, since the initial compliance conditions compliance over the following years (especially among patients under 50 years, where treatment discontinuations are more frequent and the preventive benefit high).